U1 snRNP A/B’’ antibody
- Known as:
- U1 snRNP A/B’’ (anti-)
- Catalog number:
- 10r-2349
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Fitzgerald industries international
- Gene target:
- U1 snRNP /’’ antibody
Related genes to: U1 snRNP A/B’’ antibody
- Gene:
- A1BG-AS1 NIH gene
- Name:
- A1BG antisense RNA 1
- Previous symbol:
- NCRNA00181, A1BGAS, A1BG-AS
- Synonyms:
- FLJ23569
- Chromosome:
- 19q13.43
- Locus Type:
- RNA, long non-coding
- Date approved:
- 2009-07-20
- Date modifiied:
- 2013-06-27
- Gene:
- A1CF NIH gene
- Name:
- APOBEC1 complementation factor
- Previous symbol:
- -
- Synonyms:
- ACF, ASP, ACF64, ACF65, APOBEC1CF
- Chromosome:
- 10q11.23
- Locus Type:
- gene with protein product
- Date approved:
- 2007-11-23
- Date modifiied:
- 2016-10-05
- Gene:
- A2M NIH gene
- Name:
- alpha-2-macroglobulin
- Previous symbol:
- -
- Synonyms:
- FWP007, S863-7, CPAMD5
- Chromosome:
- 12p13.31
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2018-05-03
- Gene:
- A2ML1 NIH gene
- Name:
- alpha-2-macroglobulin like 1
- Previous symbol:
- CPAMD9
- Synonyms:
- FLJ25179, p170
- Chromosome:
- 12p13.31
- Locus Type:
- gene with protein product
- Date approved:
- 2005-07-20
- Date modifiied:
- 2018-04-17
- Gene:
- A2MP1 NIH gene
- Name:
- alpha-2-macroglobulin pseudogene 1
- Previous symbol:
- A2MP
- Synonyms:
- -
- Chromosome:
- 12p13.31
- Locus Type:
- pseudogene
- Date approved:
- 1991-09-12
- Date modifiied:
- 2016-08-22
Related products to: U1 snRNP A/B’’ antibody
Related articles to: U1 snRNP A/B’’ antibody
- Bariatric surgery, particularly Roux-en-Y gastric bypass (RYGB), is an effective treatment for extreme obesity, but some patients experience inadequate weight loss or weight regain. This study aimed to identify blood biomarkers that predict effective weight loss following RYGB. - Source: PubMed
Publication date: 2026/03/09
Mahjoubin-Tehran MaryamJamialahmadi TannazSukhorukov Vasily NAlmahmeed WaelKroh MatthewSahebkar Amirhossein - - Source: PubMed
Publication date: 2026/05/13
Xiang DanYang JiaxinXiao MiaofangLong CongLin YangxuanMao ChenchenLiu XinMei DianfengXie WangkaiHan ZhengChen ChenbinLin XiaomingShen XianXue XiangyangChen Tanzhou - Breast cancer is a common malignant tumor with limited treatment options and poor prognosis. SNRPB2, a core spliceosomal component involved in pre-mRNA splicing, is dysregulated in multiple cancers, but its role in breast cancer remains incompletely understood. - Source: PubMed
Publication date: 2026/05/02
Zhang JiazhennanWang HuJia YizhenYasheng AdalaitiAi XiaoyeWang Xiuli - Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis. Small nuclear ribonucleoprotein polypeptide B (SNRPB) has been implicated in the progression of various types of cancer; however, the specific role of this protein in ESCC remains unclear. The present study aimed to investigate the expression and functional significance of SNRPB in ESCC. Bioinformatics analysis was performed to assess SNRPB expression and its clinical relevance in ESCC. Immunohistochemical staining of ESCC tissue samples demonstrated significantly elevated SNRPB expression in tumor tissues, compared with adjacent non-cancerous esophageal tissues. Analysis of public database (TCGA) and institutional clinical data revealed that high SNRPB expression was associated with poor prognosis and advanced clinical stage (T stage), respectively. To evaluate the functional role of SNRPB, a lentivirus-based short hairpin RNA vector was used to inhibit endogenous SNRPB expression in ESCC cell lines. Functional assays, including colony formation, flow cytometry and western blot analysis, demonstrated that SNRPB knockdown significantly inhibited cell proliferation, induced cell cycle arrest and promoted apoptosis. Moreover, molecular analysis indicated that SNRPB knockdown led to modulation of the cell cycle and proteins associated with apoptosis. These findings suggested that SNRPB is a key regulator of ESCC progression, through impacting cell proliferation and apoptosis. Collectively, results of the present study demonstrated that SNRPB may act as a potential prognostic biomarker and therapeutic target for ESCC. - Source: PubMed
Publication date: 2026/03/30
Guo HaiyangZuo JiHu GuangbingTang YongLu LiuyiLuo ZichenChen XinruiWang XiaoboWang Xianfei - The Solute carrier family 25 member 3 (SLC25A3), a mitochondrial solute carrier protein, has been implicated in tumor progression. Nonetheless, the connection between SLC25A3 and hepatocellular carcinoma (HCC) remains ambiguous. - Source: PubMed
Publication date: 2026/01/24
Bie BeibeiLiu LibingWang FurongMeng XianingWu MengdiSun Jin